TRex Bio, Inc. (NASDAQ:TRXB) Stock Rated “Buy” by Wall Street Analysts

Shares of TRex Bio, Inc. (NASDAQ:TRXB) have been given a consensus rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $29.67.

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. started coverage on TRex Bio in a report on Tuesday, November 3rd. They issued an “overweight” rating and a $20.00 target price for the company. Zacks Research started coverage on shares of TRex Bio in a research note on Tuesday, November 3rd. They set a “hold” rating on the stock. Evercore started coverage on shares of TRex Bio in a report on Tuesday, November 3rd. They issued a “strong-buy” rating for the company. Stifel Nicolaus initiated coverage on shares of TRex Bio in a report on Tuesday, November 3rd. They issued a “buy” rating and a $39.00 price target for the company. Finally, Cantor Fitzgerald started coverage on shares of TRex Bio in a research note on Tuesday, November 3rd. They issued an “overweight” rating for the company.

Insider Transactions at TRex Bio

In other news, major shareholder Alexandria Venture Investments bought 178,571 shares of the firm’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the transaction, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TRex Bio Stock Up 8.5%

TRex Bio stock opened at $14.25 on Thursday. TRex Bio has a 1-year low of $12.50 and a 1-year high of $16.56.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.